期刊文献+

自制阿托伐他汀钙片与立普妥的体外溶出行为相似性评价 被引量:5

Evaluation of Similarity of Dissolution Profiles between Self-made Atorvastatin Calcium Tablets and Lipitor
原文传递
导出
摘要 测定了自制阿托伐他汀钙片与立普妥在水、pH 1.2盐酸、pH 4.5乙酸盐缓冲液、pH 6.8磷酸盐缓冲液4种溶出介质中的溶出曲线,并进行相似性评价。结果表明,自制片与立普妥在水、pH 4.5乙酸盐缓冲液、pH 6.8磷酸盐缓冲液中,15min时溶出度均达85%以上,在pH 1.2盐酸中相似因子f_2为75.1。提示自制阿托伐他汀钙片与立普妥体外溶出行为相似。 The dissolution behaviors of the self-made atorvastatin calcium tablets and Lipitor in four dissolution mediums including water, hydrochloric acid (pH 1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8) were determined. The similarity of the in vitro dissolution profiles between the self-made tablets and Lipitor was evaluated. The results showed that the dissolution at 15 min of the two products were all over 85 % in water, acetate buffer (pH 4.5) and phosphate buffer (pH 6.8), and the similarity factor (f2) was 75.1 in hydrochloric acid (pH 1.2). It revealed that the dissolution behavior of the self-made product was similar to that of Lipitor.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2011年第11期823-826,共4页 Chinese Journal of Pharmaceuticals
基金 国家"重大新药创制"科技重大专项资助(2008ZX09401-004)
关键词 阿托伐他汀钙 体外溶出 相似因子 相似性评价 atorvastatin calcium in vitro dissolution similarity factor similarity evaluation
  • 相关文献

参考文献8

二级参考文献25

共引文献477

同被引文献31

  • 1张文,孙瑜,毛学建,黄选波.阿托伐他汀钙分散片溶出度的测定[J].食品与药品,2006,8(11A):49-51. 被引量:4
  • 2吴学军,邹定,何笑荣.脑啡肽酶抑制剂消旋卡多曲的药理及临床评价[J].中国新药杂志,2006,15(24):2170-2172. 被引量:43
  • 3Jan STACH, Jaroslav HAVL??EK, Luk a ? PLA?EK, et al. Synthesis of some impurities and/or degradation products of atorvastatin [J]. Collect. Czech. Chem. Co mmun. 2008, 73(2): 229-246.
  • 4CDER, FDA. Guidance for Industry: Dissolution Testing of Imme- diate Release Solid Oral Dosage Forms [EB/OL].(1997-08) [2014- 03-01] http://www.fda.gov/downloads/drugs/guidancecomplianc- eregulatoryinformation/guidances/ucm070237.pdf.
  • 5Early Breast Cancer Trialists'Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomized trials[J].The Lancet,2005,365(9742):1687-1717.
  • 6FISHER B,COSTANTINO J P,WICKERHAM D L,et a1.Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study[J].J Nat Can Ins,1998,90(18):1371-1388.
  • 7国家食品药品监督管理局.普通口服固体制剂溶出度试验技术指导原则[ED/OL].[2015-02-05][2015-07-07].http//www.sda.gov.cn/WSol/CL1616/114288.html.
  • 8张梅君,王志强,黄学荪.固体制剂溶出度的研究进展[J].中国药业,2009,18(8):58-60. 被引量:21
  • 9尉承泽,江泽飞.乳腺癌治疗基本原则和临床选择[J].中国实用外科杂志,2009,29(9):774-776. 被引量:28
  • 10程凯,徐珽,阳乐,胡海波,唐尧.阿那曲唑治疗绝经后妇女乳腺癌有效性和安全性的Meta分析[J].中国医院药学杂志,2010,30(5):431-435. 被引量:5

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部